Trading Signals: TGTX Stock Price Prediction and Forecast (Mon. Aug. 10, 2015 - Wed. Sep. 14, 2022)(TG Therapeutics Inc)
| TGTX latest price $6.8550 (-9.86%) ($6.8550 - $6.8550) on Tue. Sep. 13, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 6.75% (three month average) | RSI | 53 | Latest Price | $6.8550(-9.86%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | TGTX advances 3.1% a day on average for past five trading days. | Weekly Trend | TGTX advances 0.4% a week on average for past two weeks. | Market Behavior | Broad based sell-off for large cap. Broad based sell-off for small cap. | Correlated ETFs | Broad market will support TGTX advance at 0% a week (0% probability) HYG(95%) ONLN(96%) LQD(95%) IWC(94%) JNK(87%) | Factors Impacting TGTX price | TGTX will decline at least -3.375% in a week (0% probabilities). XRT(268%) ARKG(87%) XLRE(50%) UUP(-81%) USO(-29%) | Explanation | The rally is not sustainable and not supported by the broad market. | | | | | Relative Volatility | | | | Market Trend Strength | -3.375% (StdDev 6.75%) | Hourly BBV | -1.1 () | Intraday Trend | 0% | | | |
|
Resistance Level | $7.02 | 5 Day Moving Average | $7.07(-3.04%) | 10 Day Moving Average | $6.93(-1.08%) | 20 Day Moving Average | $7.02(-2.35%) | To recent high | -18.6% | To recent low | 83.5% | Market Cap | $868m | | | | TG Therapeutics, Inc. is a biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1101, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in New York, NY. |